Trump Slams Big Pharma — Retail Investors Are Winning

🔥‘MXRX' Planning To List On The Nasdaq

Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now—before they hit the big stage.

Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results. Their products are already available through e-commerce giants like Walmart, Amazon, and Kroger, and they plan to expand internationally.

With $6.4M in sales in just four years, they’re getting ready for the next step. Become a Med-X shareholder before their Nasdaq plans unfold.

This is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at https://invest.medx-rx.com/

💊 Trump Pressures Big Pharma: 17 Drugmakers Given 60 Days to Cut U.S. Prices

President Trump sent letters to 17 major drugmakers — from Pfizer to Eli Lilly — demanding they lower U.S. drug prices within 60 days. The move follows his executive order to tie U.S. drug prices to cheaper global rates.

📈 Retail Investors Are Beating Wall Street by Getting in Early

Confidence in government data is collapsing — and retail investors are skipping the games. They’re targeting pre-IPO opportunities and stacking gains while Wall Street is still reading outdated BLS stats.

🪙 Bullish Aims for $4.2B Valuation in U.S. IPO, Backed by Peter Thiel

Crypto exchange Bullish is looking to raise $629M via IPO — after slashing its valuation by over 50% from its SPAC-era peak. With Trump’s crypto-friendly stance and the GENIUS Act, institutional interest is rising fast.

💊 Trump Warns Pharma Tariffs Could Soar to 250% to Reshore Manufacturing

In a bold CNBC interview, Trump said he could raise pharmaceutical import tariffs to 250% — part of his plan to bring drug manufacturing back to the U.S. The warning has global suppliers on edge.

👉 That’s your Global Market News —delivering the most-read stories by 190,000+ investors like you.

No fluff. Just what moves markets and matters for your money.

— The Global Market News Team

📬 Forward this email to a friend who invests »